Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic dyslipidemia.

Marja-Riitta Taskinen1

  • 1University of Helsinki, Meilahti Hospital, Helsinki, Finland. mataskin@helsinki.fi

Atherosclerosis. Supplements
|June 5, 2002
PubMed
Summary
This summary is machine-generated.

Type 2 diabetes significantly increases cardiovascular disease risk due to dyslipidemia. Lowering LDL-cholesterol in diabetic patients offers substantial cardiovascular protection, similar to non-diabetics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Current atherosclerosis reports·2026
Same author

Multi-omics characterization of lymphedema-induced adipose tissue resulting from breast cancer-related surgery.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2024
Same author

Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol.

Journal of the American College of Cardiology·2024
Same author

Biosynthesis and Metabolism of ApoB-Containing Lipoproteins.

Annual review of nutrition·2024
Same author

Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2024
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes is a growing global epidemic, projected to affect over 300 million people by 2025.
  • Diabetes is fundamentally a vascular disease, with cardiovascular complications posing a significant threat.
  • Dyslipidemia, characterized by abnormal lipid profiles, is a key cardiovascular risk factor in type 2 diabetes.

Purpose of the Study:

  • To highlight the critical link between type 2 diabetes, dyslipidemia, and cardiovascular disease.
  • To emphasize that diabetic dyslipidemia is more atherogenic than general dyslipidemia.
  • To underscore the importance of lipid management in reducing cardiovascular events in type 2 diabetes.

Main Methods:

  • Review of existing literature and retrospective analyses on cardiovascular risk in type 2 diabetes.

Related Experiment Videos

  • Analysis of lipid particle composition in diabetic dyslipidemia.
  • Evaluation of the benefits of lipid-lowering therapies in type 2 diabetic populations.

    • Main Results:

    • Diabetic dyslipidemia involves low HDL-cholesterol, high VLDL-triglycerides, and small, dense LDL particles.
    • Even minor LDL-cholesterol elevations pose a substantial cardiovascular risk in type 2 diabetes.
    • Lipid-lowering interventions provide at least equivalent cardiovascular protection in type 2 diabetics compared to non-diabetics.

    Conclusions:

    • Addressing dyslipidemia is crucial for mitigating cardiovascular disease burden in type 2 diabetes.
    • Lowering LDL-cholesterol is a highly effective strategy for reducing coronary heart disease risk in type 2 diabetes.
    • Normal lipid levels are more atherogenic in diabetic patients, necessitating targeted lipid management.